pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,486 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1032Endpoints785BioPharma Dive299BioSpace219Fierce Biotech207onclive165raps78globenewswire health
therapy area
allOncology6122Rare Disease1471Cardiology1099Hematology1036Immunology1025Vaccines924Pulmonology
  • Presidential fitness test returns as a modest push for youth activity, experts caution limits
    The health secretary reintroduced a presidential fitness test as part of a campaign to boost youth health and address rising sedentary habits. Experts say the test is a positive step but not a com…
    STAT · 1mo agoNeutral↗ source
  • Study finds statins and blood-pressure meds bring middle-aged obese adults' heart risk markers in line with normal-weight peers
    A new 25-year observational study published in The Lancet shows that adults over 40 with obesity have blood‑pressure and cholesterol levels comparable to those of normal‑weight individuals. Resear…
    STAT · 1mo agoPositive readoutPositive↗ source
← prev
page 55 of 100
next →
73
fda recalls49
fda medwatch41
fda press28
918
Psychiatry & CNS727
Ophthalmology425
Pain406
Endocrinology & Metabolism390
Infectious Disease364
  • FDA issues warning letter to Sanofi's Genzyme Irish manufacturing site over quality and data integrity concerns
    The U.S. Food and Drug Administration sent a warning letter late last month to the Ireland‑based manufacturing facility operated by Genzyme, which is now owned by Sanofi. The agency highlighted se…
    Endpoints · 1mo agoRegulatoryNegative↗ source
  • Ipsen to acquire Swiss biotech Memo Therapeutics in up to €800 million deal for BK virus drug
    Ipsen announced it will purchase Memo Therapeutics, a Swiss biotech, in a transaction valued at up to about €800 million. The agreement provides Memo investors with €200 million upfront and potent…
    BioPharma Dive · 1mo agoDealPositive↗ source
  • FDA approves Orca Bio's T cell therapy Tregzi to lower transplant complications in blood cancer patients
    The U.S. Food and Drug Administration has granted approval to Orca Bio's T cell therapy aimed at improving outcomes for patients undergoing blood cancer transplants. The therapy, named Tregzi, is…
    Endpoints · 1mo agoApprovalPositive↗ source
  • BridgeBio secures up to $1 billion in preferred equity as United Therapeutics invests $140 million to acquire Thymmune
    BridgeBio Pharma announced that Sixth Street Partners and HealthCare Royalty will provide up to $1 billion in preferred equity to support its upcoming product launches. The financing is structured…
    BioPharma Dive · 1mo agoDealNeutral↗ source
  • BridgeBio secures $1 billion in equity financing ahead of three upcoming drug launches
    BridgeBio Pharma announced it has raised about $1 billion through a preferred equity transaction. The new capital will strengthen its balance sheet as the company prepares three potential drug lau…
    Endpoints · 1mo agoDealNeutral↗ source
  • Angitia halts Phase 3 trial of AGA111 for degenerative disc disease
    Angitia Biopharmaceuticals announced that it has ended the Phase 3 study of its investigational therapy AGA111 in patients with degenerative disc disease who had undergone lumbar interbody fusion.…
    Endpoints · 1mo agoNegative readoutNegative↗ source
  • Merck ends Phase 2 trial of Alzheimer’s drug MK-1167 from partner Neuphoria
    Merck announced it has terminated a mid-stage Phase 2 study of an experimental Alzheimer’s therapy. The drug, called MK-1167, is an oral candidate that was being developed in collaboration with bi…
    Endpoints · 1mo agoNegative↗ source
  • WuXi AppTec seeks court order to remove itself from U.S. Pentagon's Chinese military-linked company list
    WuXi AppTec has filed a petition for a preliminary injunction to halt its inclusion on the Pentagon's list of firms with alleged ties to the Chinese military. The company says the designation is d…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • Researchers claim creation of first fully synthetic cell, launch public benefit corporation to share technology
    Researchers at the University of Minnesota reported in a preprint that they have built what they call a synthetic cell, dubbed "SpudCell," which they suggest may be the first of its kind. The team…
    STAT · 1mo agoPositive↗ source
  • Anthropic launches Claude Science AI tool for pharma research labs
    Anthropic announced the availability of Claude Science, an application that tailors its large language model for use in scientific laboratories and pharmaceutical research operations. The tool is…
    STAT · 1mo agoPositive↗ source
  • STAT+: More signs that GLP-1s may help with peripheral artery disease
    Anthropic will begin developing drugs, BridgeBio pockets a billion, and more biotech news from The Readout
    STAT · 1mo agoRegulatoryNeutral↗ source
  • 92Bio revives experimental T cell engager previously handed to Amgen
    92Bio, a small California biotech, announced it is bringing back an experimental T‑cell engager it originally created before transferring the program to Amgen. The company said the candidate will…
    Endpoints · 1mo agoNeutral↗ source
  • Anthropic’s Claude Science signals AI firms are taking health research seriously
    Brittany Trang, a health‑tech reporter, notes that Anthropic’s new Claude Science model shows major AI developers are turning toward genuine scientific work rather than only high‑profile demos. Th…
    STAT · 1mo agoPositive↗ source
  • 5 FDA decisions to watch in the third quarter of 2026
    A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership.
    BioPharma Dive · 1mo ago↗ source
  • Abivax shares surge as worries subside over immune drug’s cancer risk
    According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.
    BioPharma Dive · 1mo ago↗ source
  • FDA says Zyn can market its pouches as safer than cigarettes
    The influence of the alcohol industry on policy, AI Claude for scientists, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patients
    The FDA approved a T-cell therapy from Orca Bio that reduces the risk of a debilitating immune reaction in patients with blood cancers undergoing stem cell transplants.
    STAT · 1mo ago↗ source
  • Ipsen to scoop up Memo Therapeutics and its kidney infection drug
    Ipsen is on an M&A roll. The French drugmaker announced its second deal of the week, saying it would buy Memo Therapeutics and its drug candidate called potravitug for a viral ...
    Endpoints · 1mo ago↗ source
  • A June flourish lifts biotech megaround tally in first half of 2026
    Forty private biotech companies disclosed funding rounds of $100 million or more in the first half of 2026, according to an Endpoints News tally. That's more than the same period of 2025 ...
    Endpoints · 1mo ago↗ source
  • STAT+: Booze schmooze: The alcohol industry, frazzled by headwinds, wields its power behind the scenes
    Demand for alcohol is declining. The industry is fighting harder and more creatively than ever against limits — and winning.
    STAT · 1mo ago↗ source
  • STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watch
    Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter.
    STAT · 1mo ago↗ source
  • Opinion: Maryland Gov. Wes Moore: How to improve young men’s mental health
    “We need to stop treating our young men and boys as problems to be solved, and start treating them as people to be invested in,” writes Gov. Wes Moore.
    STAT · 1mo ago↗ source
  • Opinion: What Ebola and Marburg are teaching us about the next pandemic
    “What is urgently needed is a shift from pathogen-specific diagnostics toward pathogen-agnostic diagnostic systems,” write Krutika Kuppalli and Placide Mbala.
    STAT · 1mo ago↗ source